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however, it is now impossible to propose the interval between 
the injection of the DNA and mating, the exact site and the 
amount of exogenous DNA incorporated into spermatozoa and 
the expression and stability of exogenous DNA in testes. 
Objective: In present study, we investigated the stability of 
expression of pIRES-EGFP liposome complex in rat testis after 
sperm mediated gene transfer.
Materials & Methods: A chimeric pIRES-EGFP plasmid (50 ng) 
labeled with EGFP reporter gene was mixed with cationic lipo-
some (DOTAP) in HSB solution and injected into rat testis and 
2 , 5 , 10 , 30 and 60 days post injection the testes were removed 
and the expression level of EGFP gene was examined by RT-PCR, 
Realtime PCR and ﬂuorescent microscopy. Animals which were 
injected with only DOTAP or plasmid without DOTAP were as-
signed as control groups.
Result: A ﬂuorescent microscopic observation showed that 
EGFP gene was expressed in testes from 2 to 60 days post injec-
tion. Similar results were observed when we analyzed EGFP ex-
pression by RT-PCR. Quantitative analysis of EGFP expression by 
Realtime PCR showed that its expression level was the highest in 
10 days post injection (p < 0.05). EGFP expression level was the 
lowest in 2 and 60 days after TMGT.
Conclusions: these results demonstrated that, in the case of our 
testis-mediated gene transfer, exogenous DNA injected with li-
posomes is permanently expressed 60 days after TMGT, however 
the 10 day is the best time for mating because the highest expres-
sion of foreign DNA was detected.
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Background: P53 is one of the key tumour suppressor genes 
that is targeted for inactivation during human tumour genesis. 
Point mutations or deletions in the p53 gene are found in ap-
proximately 40% of all cance .In normal cells p53 plays a crucial 
rolein the negative regulation of cell growth in response to DNA-
damage and other stress-activated signalling pathways.
Objective: In this study, we investigated the binding capacity of 
p53 mutant at codon 273 and wild type p53 to BRCA1and Rad51 in 
vivo and in vitro.
Materials & Methods: The human breast cancer cell lines, MDA-
MB-468 cells (ER- negative; hemizygous p53 mutant) and MCF-7 
cells (ER-positive; wild type p53) were used. By in vivo studied, 
the Immunoprecipitation of mutant p53 from MDA-MB-468 cells 
were compared to wild type p53 in MCF7 cells. Western blotting 
for bound p53 revealed that mutant p53 could bind BRCA1, simi-
lar wild type p53 in vivo. However, it could not bind to Rad51 in 
MDA-MB-468 cells.
In vitro studies were performed by using GST-p53 fusion protein 
which does not posttranslational modiﬁcation. We determined 
the aﬃnity of the wild type p53 fusion protein for partner pro-
teins by GST- pull down assays. 
Results:  The results from GST- pull down experiments indicated 
that the GST-p53 fusion protein retained its binding capacity for 
Rad51in MDA-MB-468 and MCF7 cell lines. GST-p53 only binds to 
BRCA1 in MDA-MB-468 cells. 
Conclusions: In conclusion, In vivo binding studies suggested 
that mutation at codon 273 of p53 did not eﬀect on its binding 
capacity to BRCA1 protein but not Rad51.Since pervious reports 
showed that BRCA1 bound physically to GST-p53, therefore the 
low levels of these proteins in our study may be the reason for 
our results. 
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Background: The enteric nervous system (ENS) is a col-
lection of neurons located in the muscular wall of the gas-
trointestinal tract (GIT) which provide the intrinsic neural 
control of vital GI functions such as motility, endocrine, mi-
crocirculation and inﬂammatory processes. Importantly, 
numerous GI disorders arise due to changes in the activity 
of the neurons which compose the ENS.  Understanding 
the underlying pathophysiology of such GI disorders is 
hindered by our lack of insight into the molecules such as 
neurotransmitters which regulate ENS neuronal function.  
Objective: Here, we investigated the expression of GABAA 
receptor (GABA
A
R) subunits in the ENS of the mouse colon 
using immunohistochemistry and confocal microscopy 
Materials & Methods: In our ongoing research, we dem-
onstrate the expression of GABA
A
 α1-5, β1-3, γ1-3 and δ sub-
units mRNA using reverse transcription PCR. We also show 
that diﬀerent GABA
A 
alpha subunits are localised to neuro-
chemically distinct populations of ENS neurons including 
those expressing Nitric oxide synthase (NOS), Choline acet-
yltransferase (ChAT), Serotonin (5-HT) and corticotropin-
releasing factor (CRF). 
Results:  Our data show the expression of GABA
A
R subunits, 
at the mRNA and protein levels, in the mouse enteric ner-
vous system which suggests that these receptors may be 
involved in the control of enteric neuronal activity. 
Conclusions: The functional implications are that diﬀer-
ent GABA
A
R subtypes are responsible for regulating the ac-
tivity of neurochemically distinct cell-types within the ENS.
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Background: Human mesenchymal stem cells (H-MSCs) 
are population of non-hematopoietic cells that have many 
applications in medicine most notably in cell therapy. De-
spite the many advantages, there are still concerns regard-
ing the use of these cells such as induction of drug resis-
tance. 
Objective: This study was performed to evaluate the eﬀects 
of   MSCs on k562 cells (human erythroleukemia cell line) 
in terms of cytotoxicyty or apoptosis following treatment 
with a well-known chemotherapy agent i.e. cytarabine
Materials & Methods: H-MSCs were isolated from 
health volunteers and characterized by ﬂowcytometery. 
MSCs were co-cultured with k562 cell line in presence of 
serial concentrations of cytarabine. As a control, K562 cells 
were also treated with cytarabine without cultivation with 
H-MSCs. The cell viability was determined by trypan blue 
exclusion test and MTT assay. Apoptosis was studied by 
ELISA kit.
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Results:  Cultivation of MSCs with k562 in the presence of 
cytarabine conferred resistance to k562.In other words, 
KLJKHUFRQFHQWUDWLRQRIF\WDUDELQHZDVUHTXLUHGWRLQGXFH
cytotoxicity when k562 cells cultivated with MSCs. Cytara-
bine also induces apoptosis cells in k562 in the concentra-
tion of (0.1-0.4μg) however and interestingly apoptosis cells 
were lower when they co-cultured with MSCs.
Conclusions: This study indicated that MSCs confer resis-
tance to erythroleukemia cell line following treatment with 
chemotherapy agent and prevent leukemic cells apoptosis. 
Our ﬁnding may open new window why erythroleukemia 
cell become resistance to chemotherapy and may suggest 
new strategy for treatment of them.
Keywords: H-MSC, K562 Cells, Cytarabine, Apoptosis 
O-1-9103-Evaluation of DNA strand breaks associated 
with apoptosis in lymphocytes of Phototherapy-treat-
ed icteric newborns
Maryam Shahidi1, Seyed Alireza Mesbah-Namin2
1. Department of Biochemistry and Biophysics, Mazandaran 
University of Medical Sciences, Sari, Iran
2. Department of Clinical Biochemistry, Tarbiat Modares 
University, Tehran, Iran
Background: The aim of this study was to evaluate the DNA 
double strand breaks associated with apoptosis in hyper-
bilirubinemic newborns during continues phototherapy.
Materials & Methods: Neutral comet assay was used to 
evaluate DNA damage levels and apoptosis value in periph-
eral blood lymphocytes from 15 healthy full term newborns 
with physiological jaundice (bilirubin levels  <  13 mg/dl) 
as the control group (not receiving phototherapy) and 30 
healthy newborns with non-physiological jaundice (biliru-
bin levels >13 mg/dl) undergoing 16 hours continues pho-
totherapy (wavelength range was about 480-520nm) as the 
phototherapy-treated group. 
Results:  Neutral comet assay results showed that DNA 
damage signiﬁcantly decreased in peripheral blood lym-
phocytes from phototherapy-treated newborns during 
24-hours incubation, while apoptosis value signiﬁcantly 
increased at the same time. 
Discussion : These ﬁnding indicated that DNA double 
strand breaks associated with apoptosis signiﬁcantly in-
creased after phototherapy in hyperbilirubinemic new-
born’s lymphocytes compared with the control group. 
Further studies are needed to evaluate of the phototherapy 
eﬀects observed in this study on the long-term health in 
jaundiced newborns. 
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Background: Hepatocellular carcinoma (HCC) is one the 
most common cause of death in the world and it treatment 
failure is still a major problem in scientiﬁc circles. Metho-
trexate has been used for decades to treat psoriasis and 
some cancers but chemotherapy resistance is a major ob-
stacle in the treatment of liver cancer. ICG-001 is a selective 
Wnt/ß-catenin signaling inhibitor that binds to the amino 
terminus of CREB, thus preventing ß-catenin/TCF signaling 
in the nucleus 
Objctive: In this study, we intend to determine the impor-
tant markers in related to chemo-therapy resistance in 
HepG2 as a MTX-resistance cell line after it treatment with 
ICG-001.
Materials & Methods :Cell culture and MTT assay of HepG2 for 
MXT resistance and ICG-001 treatment, RT-PCR for b-catenine, lgr-
5, MDR-1, Hif-1(alpha) and NF-kB factors expression, and western 
blot analysis of caspase 3, 9, bcl-2 and Livin.
Conclusion: These data indicate targeting Wnt/ß-catenin Path-
way with ICG-001 could inhibit apoptosis and also somewhat re-
duce chemotherapy resistance.
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Background: Numerous reports have beenrecently published 
on the misregulatedexpression of long non-coding RNAs (Ln-
cRNAs) invarious cancer types, suggesting that abnormal expres-
sion of LncRNAs is a major contributor to tumorigenesis. A broad 
spectrum of LncRNAs is expressed in central nervous system 
(CNS), where these transcripts have been shown to play indis-
pensable roles in brain development and function. 
Objective: So X2OT isaLncRNA gene with a proposed role in the 
regulation of neural development. Interestingly, it also embeds 
SOX2, a master regulator of pluripotency, in its 3rdintron.Based 
on our previous studies, alternative splicing of SOX2OT gener-
ates several spliced variants.
Materials & Methods: In the present study, we investigated 
the expression pattern of two SOX2OT variants (SOX2OT-S1 and 
SOX2OT-S2) in three types of brain tumors (Glioma, Meningioma, 
and Adenoma). Total RNA was extracted from 35 brain tumor 
samples, and the expression of both S1 and S2 variants was mea-
sured using real-time RT-PCR.
Results:  Our data revealed a diﬀerential expression ofS1 and S2 
variants in diﬀerent brain tumors, in a way that its expression 
level could discriminate glioma, meningioma and adenoma tu-
mors from each others (P  <  0.05). In conclusion, the diﬀeren-
tial expression and splicing of SOX2OT in diﬀerent types of brain 
tumors indicates a potential involvement of SOX2OT variants in 
brain tumorigenesis.
Conclusions: Our data also highlights a potential usefulness of 
SOX2OT variants in molecular diagnosis and classiﬁcation of dif-
ferent types of brain tumors.
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Background: Receptor-mediated estrogen activation partici-
pates in the development and progression of breast cancer. Evi-
dence suggests that alterations in estrogen signaling pathways, 
including estrogen receptor-a (ESR1) occur during breast cancer 
development. ESR1 gene polymorphism has been found to be as-
